A research letter published in Experimental Dermatology written by Chang-Yu Hsieh from the Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan, entitled,.
New data suggests that patients with psoriasis may see positive outcomes after switching from secukinumab 150 mg to risankizumab 75 mg if secukinumab responses are inadequate.